Table 3.
Quantitative analysis and comparison of the pre- and posttreatment results of the 3 × 3 mm scan group.
| Metric | Pretreatment | Posttreatment | Change | % change | p valuea |
|---|---|---|---|---|---|
| LogMAR CDVA (mean ± SD) | 0.63 ± 0.34 | 0.51 ± 0.38 | −0.12 ± 0.24 | −19% | 0.122b |
| CMT (mean ± SD), μm | 370 ± 69 | 276 ± 51 | −93 ± 74 | −25.1% | 0.008b |
| PFT (mean ± SD), μm | 384 ± 34 | 331 ± 25 | −53 ± 42 | −13.8% | 0.005c |
| IOP (mean ± SD), mmHg | 17.8 ± 1.9 | 15.7 ± 2.7 | −2.5 ± 2.6 | −14% | 0.064c |
| Signal strength (mean ± SD) | 5.9 ± 1.4 | 6.3 ± 1.1 | 0.4 ± 0.9 | 6.8% | 0.169c |
| FAZ area (mean ± SD), mm2 | 0.36 ± 0.09 | 0.39 ± 0.12 | 0.03 ± 0.04 | 8.3% | 0.067c |
| FD-Full (mean ± SD) | 1.53 ± 0.03 | 1.49 ± 0.04 | −0.04 ± 0.05 | −2.6% | 0.046c |
| FD-SCP (mean ± SD) | 1.48 ± 0.05 | 1.43 ± 0.06 | −0.05 ± 0.05 | −3.4% | 0.01c |
| FD-DCP (mean ± SD) | 1.53 ± 0.04 | 1.49 ± 0.05 | −0.04 ± 0.06 | −2.6% | 0.073c |
| VD-Full (mean ± SD), % | 29.5 ± 5.97 | 26.1 ± 7.67 | −3.38 ± 4.08 | −11.5% | 0.038c |
| VD-SCP (mean ± SD), % | 22.9 ± 6.17 | 19.7 ± 6.3 | −3.27 ± 3.18 | −14.3% | 0.015c |
| VD-DCP (mean ± SD), % | 26.2 ± 6.22 | 23.9 ± 7.32 | −2.3 ± 3.95 | −8.8% | 0.118c |
| Skeleton VD-Full (mean ± SD), % | 6.93 ± 1.4 | 5.65 ± 1.6 | −1.28 ± 1.75 | −18.5% | 0.059c |
| Skeleton VD-SCP (mean ± SD), % | 5.45 ± 1.6 | 4.09 ± 1.3 | −1.37 ± 1.2 | −25.1% | 0.009c |
| Skeleton VD-DCP (mean ± SD), % | 6.86 ± 1.6 | 5.52 ± 1.5 | −1.35 ± 1.9 | −19.7% | 0.066c |
CDVA, corrected distance visual acuity; CMT, central macular thickness; DCP, deep capillary plexus; FAZ, foveal avascular zone; FD, fractal dimension; Full, full retinal thickness; IOP, intraocular pressure; LogMAR, logarithm of the minimum angle of resolution; PFT, parafoveal thickness; SCP, superficial capillary plexus; VD, vascular density. aStatistically significant if <0.05. bWilcoxon signed rank test. cPaired t-test.